Comparison of clinical features of patients with AL amyloidosis treated with HDM/SCT (n = 312) according to availability of baseline SF-36 data
Feature . | SF-36 completed; n = 251 . | SF-36 unavailable; n = 61 . | P . |
|---|---|---|---|
| Age, y, mean | 56.5 ± 9.5 | 55.9 ± 13.5 | .755 |
| Mo from first symptom to diagnosis* | 7.2 (3.2, 13.4) | 7.1 (3.2, 14.4) | .702 |
| Mo from diagnosis to referral* | 2.6 (1.5, 4.9) | 2.7 (1.5, 4.8) | .700 |
| Performance status greater than 1, % | 26.4 | 25.0 | .665 |
| Performance status* | 1 (1, 2) | 1 (1, 2) | .772 |
| Number of organ systems involved* | 3 (2, 3) | 3 (2, 3) | .809 |
| Organ involvement, % | |||
| Heart | 44.6 | 41.0 | .608 |
| Kidney | 87.7 | 88.5 | .851 |
| Gastrointestinal/liver | 56.6 | 52.5 | .562 |
| Neuropathy | 49.8 | 50.8 | .887 |
| Soft tissue | 19.5 | 21.3 | .753 |
Feature . | SF-36 completed; n = 251 . | SF-36 unavailable; n = 61 . | P . |
|---|---|---|---|
| Age, y, mean | 56.5 ± 9.5 | 55.9 ± 13.5 | .755 |
| Mo from first symptom to diagnosis* | 7.2 (3.2, 13.4) | 7.1 (3.2, 14.4) | .702 |
| Mo from diagnosis to referral* | 2.6 (1.5, 4.9) | 2.7 (1.5, 4.8) | .700 |
| Performance status greater than 1, % | 26.4 | 25.0 | .665 |
| Performance status* | 1 (1, 2) | 1 (1, 2) | .772 |
| Number of organ systems involved* | 3 (2, 3) | 3 (2, 3) | .809 |
| Organ involvement, % | |||
| Heart | 44.6 | 41.0 | .608 |
| Kidney | 87.7 | 88.5 | .851 |
| Gastrointestinal/liver | 56.6 | 52.5 | .562 |
| Neuropathy | 49.8 | 50.8 | .887 |
| Soft tissue | 19.5 | 21.3 | .753 |
Data represented as median (25th percentile, 75th percentile).